Wegovy Pill Weight Loss: Real-World Users Lose 6.2% in Three Months
Real-world data on 5,872 Ro patients show the once-daily Wegovy pill delivered 6.2% average weight loss in three months, slightly above trial results.
Real-world data on 5,872 Ro patients show the once-daily Wegovy pill delivered 6.2% average weight loss in three months, slightly above trial results.
Eugia US, Aurobindo Pharma's injectables arm, has recalled one nationwide lot of vancomycin 1.25 g vials after a glass particle was found. Lot details, risks and what hospitals should do.
Health Canada found Sphingomonas bacteria in an injectable peptide seized in Ottawa and named 11 unauthorized products, including BPC-157 and retatrutide.
What the HRV Pharma Phatebo acquisition means: a Hyderabad API specialist buys a German clinical-trial supply firm, price and closing date undisclosed.
What the Lupin Q2 FY27 results show: sales up 14% to ₹7,786 crore, net profit down 22.2%, and how the US, India and other regions contributed.
What the Emcure Pharma Q2 FY27 results show: revenue up 24.3%, international sales up 34.5% and a raised full-year revenue growth outlook above 20%.
Why the Shilpa CDMO $50 million investment matters: a Raichur peptide line planned for December 2026, 1 tonne a year at first, and what is not yet running.
Behind the Alembic Pharmaceuticals Q2 FY27 results: US up 77%, API up 39%, India up 14% and ex-US up 12%, driving an 81% profit jump.
The Teva Samsung Bioepis biosimilar agreement hands Teva US rights to two older biosimilars; here is what changes, when, and what is not disclosed.
The Teva Q3 2026 results show revenue down 2% to $4.4 billion while non-GAAP margin and EPS improved, led by Austedo, Ajovy and Uzedy growth.